Anteris Technologies has received full regulatory clearance from Germany to expand its PARADIGM trial for the DurAVR transcatheter heart valve, targeting patients with severe calcific aortic stenosis. This approval allows the company to recruit patients in Germany, Europe's largest market for transcatheter aortic valve replacement, leveraging the country's advanced clinical centers to potentially speed up enrollment. The PARADIGM trial aims to enroll around 1,000 patients globally, comparing DurAVR to existing commercial devices to assess safety and effectiveness. This expansion is a significant step in Anteris' global clinical program across the US and Europe.
Anteris Technologies' regulatory progress in Germany is noted alongside the health sector's market breadth on Pluang, where 83 of 150 US health stocks rose as of Oct 20, 2026 08:51 WIB. Among notable movers were SELLAS Life Sciences Group Inc. (SLS) up 5.71% at USD 10.55, Hinge Health Inc. (HNGE) up 4.84% at USD 103.96, and Relay Therapeutics Inc. (RLAY) up 4.79% at USD 17.06. This snapshot provides a view of health sector activity on Pluang at the given time.
Anteris Technologies received regulatory approval from Germany's BfArM to start enrolling patients in its global PARADIGM trial for the DurAVR Transcatheter Heart Valve. This approval allows the company to recruit patients at leading German centers, ...
XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...
XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...
Hyperliquid (HYPE) has surpassed Bitcoin (BTC) and Ether (ETH) in a 30-day analyst sentiment index, indicating a more positive outlook from market analysts over the past month. The index, which updates hourly and counts one vote per analyst, measures...
Grupo Aeroportuario del Pacífico reported a 21.8% increase in total revenues for Q3 2026, driven by higher aeronautical and non-aeronautical services and the integration of Cross Border Xpress (CBX). Net income rose 8.1% to Ps. 2.91 billion despite a...
